BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:basiliximab (Simulect) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of basiliximab (Simulect)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05139004-9685@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20270613
DTEND;VALUE=DATE:20270614
SUMMARY:basiliximab (Simulect): Phase 1 readout est. (NCT05139004)
DESCRIPTION:basiliximab (Simulect)\, phase 1.\nStudy: 90Y-DOTA-anti-CD25 Ba
 siliximab\, Fludarabine\, Melphalan\, and Total Marrow and Lymphoid Irradi
 ation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syn
 drome\nEstimated primary completion: 13 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/basiliximab-simulect#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05139004
URL:https://assetmemo.bio/drug/basiliximab-simulect#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04871607-9685@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:basiliximab (Simulect): Phase 2 readout est. (NCT04871607)
DESCRIPTION:basiliximab (Simulect)\, phase 2.\nStudy: Yttrium-90 Labeled An
 ti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning f
 or the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma\nEstim
 ated primary completion: 2 October 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/basiliximab-simulect#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04871607
URL:https://assetmemo.bio/drug/basiliximab-simulect#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
